Treatment capacity required for full-scale implementation of lung cancer screening in the United States by Blom, E.F. (Erik) et al.
2039Cancer  June 15, 2019
Original Article
Treatment Capacity Required for Full-Scale Implementation  
of Lung Cancer Screening in the United States
Erik F. Blom, MD 1; Kevin ten Haaf, PhD1; Douglas A. Arenberg, MD2; and Harry J. de Koning, MD, PhD1
BACKGROUND: Full-scale implementation of lung cancer screening in the United States will increase detection of early stages. This 
study was aimed at assessing the capacity required for treating those cancers. METHODS: A well-established microsimulation model 
was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when 
implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smok-
ers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack-years (US Preventive Services 
Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years 
ago, aged 55 to 77 years, with a smoking history of at least 30 pack-years (Centers for Medicare and Medicaid Services [CMS] recom-
mendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, 
with a smoking history of at least 40 pack-years (the most cost-effective policy in Ontario [Ontario]). The base-case screening 
 adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 
and 2027. RESULTS: The USPSTF policy would require 37.0% more lung cancer surgeries in 2015-2040 than no screening, 2.2% less 
radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 
96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand 
would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand 
would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, 
 although the changes in comparison with no screening were smaller. CONCLUSIONS: Full-scale implementation of lung cancer 
screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread 
this peak over time. Careful surgical capacity planning is essential for successfully implementing screening. Cancer 2019;125:2039-2048. 
© 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article 
under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any 
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
Despite decreasing incidence rates, lung cancer is still the leading cause of cancer-related mortality in the United States.1 
The National Lung Screening Trial (NLST) has shown that 3 annual low-dose computed tomography (LDCT) screen-
ings for lung cancer can reduce lung cancer mortality by 20% in comparison with 3 annual chest radiography screen-
ings.2 Since then, both the US Preventive Services Task Force (USPSTF)3 and the Centers for Medicare and Medicaid 
Services (CMS)4 have issued recommendations for LDCT screening for lung cancer. The USPSTF recommendations 
have been partly based on modeling efforts.5
The standard of care is surgery for early-stage non–small cell lung cancer (NSCLC), a combination of chemo-
therapy and radiotherapy for locally advanced NSCLC, and chemotherapy for advanced NSCLC.6 Consequently, early 
detection by lung cancer screening is expected to increase the demand for surgery and decrease the demand for radio-
therapy and chemotherapy. The magnitude of this shift in treatment will depend on the number of screened individuals, 
which will decrease over time7 because younger birth cohorts smoke less.8
The benefits of early detection depend on the availability of adequate treatment. Hence, assessing the demand for 
treatment and planning for sufficient manpower are essential to successfully implementing screening. In screening pro-
grams where capacity (eg, for follow-up) has been limited, program implementation has been done gradually to take this 
into account.9 Therefore, the aim of the current study was to project the treatment capacity required for the full-scale 
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implementation of LDCT screening for lung cancer in 
the United States.
MATERIALS AND METHODS
Simulation of Lung Cancer Incidence Rates
In this study, we used the Microsimulation Screening 
Analysis Lung (MISCAN-Lung) model, which simu-
lates individual life histories in the presence and absence 
of screening to project benefits and harms of different 
screening policies on a population level. This study was 
deemed exempt by the Institutional Review Board at the 
University of Michigan. MISCAN-Lung has been cali-
brated to individual-level incidence and mortality data 
from the NLST and the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial.10,11 It accounts for differ-
ences in smoking behavior across birth cohorts by incor-
porating the National Cancer Institute’s Smoking History 
Generator.8 The model has been previously used to inform 
the USPSTF on the LDCT screening scenario with the 
most favorable ratio of benefits and harms for a 1950 US 
birth cohort.5 Also, it has been used to identify the most 
cost-effective scenario for Cancer Care Ontario.12
In the current analysis, we first simulated a scenario 
without lung cancer screening. Then, we simulated 3 
 scenarios with screening: 1) using the USPSTF recommen-
dations (ie, annual screening of current smokers and former 
smokers who quit fewer than 15 years ago, aged 55-80 years, 
with a smoking history of at least 30 pack-years),3 2) using 
the CMS recommendations (ie, stopping screening 3 years 
earlier than the USPSTF scenario at the age of 77 years),4 
and 3) using the most cost-effective policy from a  recent 
cost-effectiveness analysis for Cancer Care Ontario 
(ie, annual screening of current smokers and former smok-
ers who quit fewer than 10 years ago, aged 55-75 years, 
with a smoking history of at least 40 pack-years).12
The timeframe for this study was 2015-2040. We 
assumed that screening started in 2018 because the cur-
rent uptake of lung cancer screening in the United States 
is low.13 We simulated the full range of birth-year cohorts 
from 1916 (ie, patients aged 99 years in 2015) through 
2005 (ie, patients aged 35 years in 2040). We assumed 
that no lung cancer occurred under the age of 35 years. 
We further assumed that the maximum age in the popu-
lation was 99 years.
Treatment Capacity Requirements
For each screening scenario, we adjusted the year-, 
sex-, age-, stage-, and histology-specific lung can-
cer incidence rates estimated by MISCAN-Lung to 
the projected US population by using the US Census 
National Population Projections.14 Therefore, we 
accounted for growth and aging of the population. 
Next, we obtained lung cancer treatment patterns from 
the National Cancer Database (NCDB) participant user 
file for 440,566 lung cancer cases diagnosed between 
2010 and 2014. The NCDB, established in 1989, is a 
nationwide, facility-based, comprehensive clinical sur-
veillance resource oncology data set that currently 
captures 70% of all newly diagnosed malignancies 
in the United States annually from more than 1500 
affiliated facilities. The NCDB is a joint project of the 
Commission on Cancer of the American College of 
Surgeons and the American Cancer Society. An analysis 
of individual-level NCDB data was performed on site 
at the University of Michigan Medical School. Details 
of the analysis of the NCDB data, including case selec-
tion and data cleaning, are provided as supplementary 
methods in the supporting information. In short, we 
obtained the sex-, age-, stage-, and histology-specific 
proportions of patients with lung cancer who received 
surgery, radiotherapy, chemotherapy, and any therapy 
as first-course treatment. Because treatment patterns 
among patients with lung cancer in the NCDB remained 
stable over time (see Supporting Fig. 1), the mean treat-
ment proportions across years 2010-2014 were used in 
this study (see Supporting Table 1). For each scenario 
that we simulated, we then calculated the required lung 
cancer treatment capacity by multiplying the year-, sex-, 
age-, stage-, and histology-specific Census-adjusted in-
cidence from MISCAN-Lung with the mean sex-, age-, 
stage-, and histology-specific treatment proportions 
from the NCDB. In the base-case analysis, the same 
treatment proportions were applied to screen-detected 
cases and clinically detected cases. Because screen- 
detected cases may have less comorbidity than clinically 
detected cases, a sensitivity analysis was also performed 
that used stage-specific treatment proportions from the 
LDCT arm of the NLST for screen-detected cases (see 
Supporting Table 2).2
Effect of Adherence
On the basis of the results of an implementation study 
of lung cancer screening in the US Veterans Affairs 
Administration, we assumed a constant screening 
adherence of 50% for the base-case analysis.15 Another 
study in the Stanford Health Care system reported an 
adherence level of 60%.16 That study also reported 
national adherence rates of 69% for colorectal cancer 
screening, 79% for breast cancer screening, and 75% 
for cervical cancer screening in the United States. We 
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assume that it is unlikely that adherence to lung cancer 
screening will surpass that of existing screening pro-
grams in the near future. Therefore, we assessed the 
effect of constant adherence levels of 20%, 35%, 65%, 
and 80% in a sensitivity analysis. In a second sensitiv-
ity analysis, we assessed the effect of a linear buildup 
of screening adherence from 5% in 2018 to a plateau of 
50% from 2027 onward.
Statistical Analysis
All analyses were performed with the MISCAN-Lung 
model and R software (version 3.4.1).17
RESULTS
Simulation of Lung Cancer Incidence Rates
In 2018, the projected number of screening-eligible per-
sons in the US population would be 11,816,790 for the 
USPSTF scenario, 11,258,937 for the CMS scenario, 
and 6,505,609 for the Ontario scenario (Supporting 
Fig. 2). By 2023, screening eligibility would decrease to 
10,192,541 (USPSTF), 9,574,244 (CMS), and 5,548,430 
(Ontario). By 2040, 4,710,017 persons would be eligible 
in the USPSTF scenario, 4,145,176 would be eligible 
in the CMS scenario, and 2,322,388 would be eligible 
according to the Ontario criteria.
In the absence of screening, annual Census-adjusted 
lung cancer incidence would increase to 215,392 cases by 
2033 and would then gradually decrease (see Supporting 
Fig. 3). The implementation in 2018 of a screening 
program with a constant 50% adherence would lead to 
an immediate peak in incidence in comparison with no 
screening. This peak would be highest for the USPSTF 
scenario (n = 253,938), which would be followed by the 
CMS scenario (n = 247,556) and the Ontario scenario 
(n = 233,841). With a gradual buildup of adherence, this 
peak would be lower but last longer (Supporting Fig. 4).
Over the entire study period, the cumulative num-
ber of lung cancer cases would be 5,525,593 for the 
USPSTF scenario, 5,495,049 for the CMS scenario, 
5,462,657 for the Ontario scenario, and 5,402,854 for 
the no-screening scenario (Supporting Table 3). The 
proportions of screen-detected cases would be 16.8% 
(USPSTF), 14.3% (CMS), and 10.1% (Ontario). In the 
absence of screening, 22.2% of clinically detected cases 
would be diagnosed at stage I, 5.9% would be diag-
nosed at stage II, 25.5% would be diagnosed at stage III, 
Figure 1. Distribution of stages at diagnosis for (A) clinically detected lung cancer cases, (B) screen-detected cases, and 
(C) all cases in the United States between 2015 and 2040 in the absence of low-dose computed tomography screening and for the 
3 screening policies implemented in 2018. All policies assumed a constant 50% adherence to screening. CMS indicates Centers 
for Medicare and Medicaid Services recommendations (annual screening of current smokers and former smokers who quit fewer 
than 15 years ago, aged 55-77 years, with a smoking history of at least 30 pack-years); Ontario, most cost-effective policy from a 
study for Cancer Care Ontario (annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 
55-75 years, with a smoking history of at least 40 pack-years); USPSTF, US Preventive Services Task Force recommendations 
(annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55-80 years, with a smoking 
history of at least 30 pack-years).
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and 46.3% would be diagnosed at stage IV (see Fig. 1A). 
Among screen-detected cases in the USPSTF scenario, 
65.6% would be diagnosed at stage I, 6.8% would 
be diagnosed at stage II, 16.5% would be diagnosed 
at stage III, and 11.1% would be diagnosed at stage 
IV (see Fig. 1B). For both clinically detected and 
screen-detected cases, differences in stage distributions 
across scenarios were minimal. Overall, the proportion 
of cases diagnosed at stage I would be 30.6% in the 
USPSTF scenario, 29.4% in the CMS scenario, 27.3% 
in the Ontario scenario, and 22.2% without screening 
(see Fig. 1C). Conversely, the proportion of cases diag-
nosed at stage IV would decrease because of screening: 
from 46.3% without screening to 38.9% (USPSTF), 
40.0% (CMS), and 41.8% (Ontario).
Treatment Capacity Requirements
Figure 2 shows the changes in lung cancer therapy due 
to the implementation of LDCT screening in 2018. 
The main change would be a large cumulative increase 
in the demand for lung cancer surgery. At the base-case 
adherence of 50%, the demand for lung cancer surgery 
would increase in comparison with no screening by 
37.0% (USPSTF), 32.1% (CMS), and 22.8% (Ontario). 
However, the demand for radiotherapy would decrease 
by 2.2% (USPSTF), 2.6% (CMS), and 2.1% (Ontario). 
The demand for chemotherapy would decrease by 5.4% 
(USPSTF), 5.1% (CMS), and 3.8% (Ontario). Finally, 
the number of patients who would receive any therapy 
would increase by 5.7% (USPSTF), 4.5% (CMS), and 
3.0% (Ontario). If we assume that screen-detected cases 
would receive stage-specific treatment as reported in the 
NLST, the increase in surgery in comparison with no 
screening would be 55.3% (USPSTF), 46.3% (CMS), 
and 32.3% (Ontario; Supporting Fig. 5). The demand 
for radiotherapy would decrease by 7.4% (USPSTF), 
6.8% (CMS), and 5.1% (Ontario). Chemotherapy 
demand would decrease by 4.3% (USPSTF), 4.7% 
(CMS), and 3.7% (Ontario). Finally, the demand for 
any therapy would increase by 7.6% (USPSTF), 5.9% 
(CMS), and 3.9% (Ontario).
Figure 3 shows the absolute annual number of lung 
cancer treatments required between 2015 and 2040 for 
the base-case scenario. Supporting Table 4 additionally 
shows the percentage change in comparison with no 
screening in 2018, 2023, 2028, and 2040. In the absence 
of screening, the annual required number of lung can-
cer surgeries would remain relatively constant: 37,964 
in 2018, 38,903 in 2023, 38,876 in 2028, and 34,021 
in 2040. Implementing the USPSTF recommendations 
would increase demand for lung cancer surgery in com-
parison with no screening by 96.1% in 2018, 46.0% in 
2023, 38.3% in 2028, and 24.9% in 2040. In the CMS 
scenario, the increases in comparison with no screening 
would be 87.5% (2018), 41.2% (2023), 33.0% (2028), 
and 19.7% (2040). Finally, implementing the Ontario 
recommendations would increase demand in compari-
son with no screening by 64.5% in 2018, 30.1% in 2023, 
23.7% in 2028, and 13.1% in 2040.
In the absence of screening, the annual number of 
patients with lung cancer requiring radiotherapy would 
increase from 81,802 in 2018 to 84,378 in 2023 and 
85,242 in 2028, after which it would gradually decrease 
to 81,219 in 2040. Implementing the USPSTF recom-
mendations would first increase demand for radiotherapy 
by 20.7% in 2018. However, demand would decrease in 
Figure 2. Cumulative changes in demand for lung cancer 
therapy in the United States between 2015 and 2040 with 
the implementation of low-dose computed tomography 
screening for lung cancer in 2018. The data are expressed 
as cumulative percentage changes in comparison with no 
screening. All policies assumed a constant 50% adherence 
to screening. CMS indicates Centers for Medicare and 
Medicaid Services recommendations (annual screening of 
current smokers and former smokers who quit fewer than 
15 years ago, aged 55-77 years, with a smoking history of 
at least 30 pack-years); Ontario, most cost-effective policy 
from a study for Cancer Care Ontario (annual screening of 
current smokers and former smokers who quit fewer than 
10 years ago, aged 55-75 years, with a smoking history of 
at least 40 pack-years); USPSTF, US Preventive Services 
Task Force recommendations (annual screening of current 
smokers and former smokers who quit fewer than 15 years 
ago, aged 55-80 years, with a smoking history of at least 
30 pack-years).
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comparison with no screening shortly after that by 4.7% 
in 2023, 5.1% in 2028, and 3.3% in 2040. Results for 
the CMS and Ontario scenarios were similar, although 
differences in comparison with no screening were less 
pronounced.
We found a similar pattern for the number of cases 
that required chemotherapy. In the absence of screening, 
the demand for chemotherapy would be 83,221 in 2018, 
84,351 in 2023, 83,366 in 2028, and 72,586 in 2040. In 
the USPSTF scenario, demand would first increase by 
Figure 3. Absolute annual number of patients with lung cancer in the United States requiring (A) surgery, (B) radiotherapy, 
(C) chemotherapy, and (D) any therapy with the implementation of low-dose computed tomography screening for lung cancer 
in 2018. All policies assumed a constant 50% adherence to screening. CMS indicates Centers for Medicare and Medicaid Services 
recommendations (annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55-77 years, 
with a smoking history of at least 30 pack-years); Ontario, most cost-effective policy from a study for Cancer Care Ontario (annual 
screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55-75 years, with a smoking history of 
at least 40 pack-years); USPSTF, US Preventive Services Task Force recommendations (annual screening of current smokers and 
former smokers who quit fewer than 15 years ago, aged 55-80 years, with a smoking history of at least 30 pack-years).
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18.7% in 2018, and this would be followed by relative 
decreases in comparison with no screening of 9.0% in 
2023 and 2028 and 6.2% in 2040.
Finally, the number of lung cancer cases that would 
receive any therapy in the no-screening scenario would 
increase from 141,751 in 2018 to 146,288 in 2023 and 
147,815 in 2028. Then, it would decrease to 137,607 in 
2040. For each screening scenario, the number of cases 
receiving any therapy peaked in 2018: +36.5% (USPSTF), 
+32.7% (CMS), and +23.8% (Ontario) in comparison 
with no screening. The difference in comparison with no 
screening would then become smaller within the 5 years 
after implementation. For the USPSTF scenario, the in-
crease in comparison with no screening would be 5.9% in 
2023, 3.8% in 2028, and 2.1% in 2040.
Effect of Adherence
Figure 4 shows the effect of different levels of constant 
screening adherence on the number of patients requiring 
lung cancer surgery for the USPSTF scenario. In 2018, 
the required surgical capacity would be 52,619 (20% 
 adherence), 63,623 (35%), 74,437 (50%), 85,312 (65%), 
and 96,121 (80%). If we consider 20% adherence as the 
lower limit and 80% adherence as the upper limit, the 
number of surgeries would range from 47,790 to 62,849 
in 2023, from 46,213 to 58,752 in 2028, and from 38,259 
to 45,172 in 2040. Results for the CMS and Ontario 
scenarios are shown in Supporting Figures 6 and 7, 
respectively.
Figure 5 and Supporting Table 5 show the effect 
of a linear buildup of screening adherence from 5% in 
2018 to a constant 50% from 2027 onward. In 2018, 
the increases in surgical demand in comparison with no 
screening would be 9.6% (USPSTF), 8.7% (CMS), and 
7.9% (Ontario). In 2023, the increases would be 38.3% 
(USPSTF), 34.2% (CMS), and 30.4% (Ontario). In 
2028, the increases would be 42.0% (USPSTF), 36.1% 
(CMS), and 31.6% (Ontario). Finally, in 2040, the 
increases would be 24.4% (USPSTF), 19.4% (CMS), and 
16.1% (Ontario). For the USPSTF scenario, the demand 
for radiotherapy would change in comparison with no 
screening by +2.1% (in year 2018), +1.7% (2023), –2.9% 
(2028), and –3.4% (2024). Demand for chemotherapy 
would change by +1.9% (2018), –0.6% (2023), –6.8% 
(2028), and –6.2% (2040). Finally, demand for any 
therapy would change by +3.7% (2018), +9.3% (2023), 
+6.3% (2028), and +1.9% (2040). Changes in the 
demand for radiotherapy, chemotherapy, and any therapy 
for the CMS and Ontario scenarios were similar to the 
USPSTF scenario but less pronounced.
DISCUSSION
The aim of this study was to quantify the expected treat-
ment capacity required for the full-scale implementation 
of LDCT screening for lung cancer in the United States.
Simulation of Lung Cancer Incidence Rates
The introduction of screening caused an immediate 
peak in lung cancer incidence. This initial peak can be 
explained by the lead time of screen-detected preclini-
cal cases, which would have otherwise been clinically 
detected later in time.
We found that screening caused a shift in the stage 
at diagnosis from stage IV to stage I. This stage shift 
was more pronounced for scenarios with less stringent 
eligibility criteria (ie, stage shift for USPSTF > stage 
shift for CMS > stage shift for Ontario). This may be 
explained by the higher number (and proportion) of 
screen-detected cases in those scenarios (see Supporting 
Table 3). In the NLST, which followed participants 
from 2002 to 2009, the proportion of stage I lung 
cancers in the LDCT arm was 50.0%.2 This is much 
higher than the 30.6% that we found in the USPSTF 
Figure 4. Absolute annual number of patients with lung cancer 
in the United States requiring surgery with the implementation 
of low-dose computed tomography screening for lung cancer 
in 2018 using the US Preventive Services Task Force criteria 
at different constant screening adherence levels. USPSTF 
indicates US Preventive Services Task Force recommendations 
(annual screening of current smokers and former smokers who 
quit fewer than 15 years ago, aged 55-80 years, with a smoking 
history of at least 30 pack-years).
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scenario. This difference may be explained by 3 factors. 
Most importantly, our simulation of the general pop-
ulation included all lung cancer cases, not just those 
detected in the screen-eligible population. Second, we 
conducted our model under assumptions of much lower 
(and perhaps more realistic) screening adherence (50%) 
than was achieved in the NLST (>90%).2 Third, our 
results were projected from 2015 to 2040 and, therefore, 
Figure 5. Absolute annual number of patients with lung cancer in the United States requiring (A) surgery, (B) radiotherapy, 
(C) chemotherapy, and (D) any therapy with the implementation of low-dose computed tomography screening for lung cancer 
in 2018. All policies assume an adherence level of 5% in 2018 with an annual increase of 5 percentage points until a constant 
adherence of 50% is reached in 2027. CMS indicates Centers for Medicare and Medicaid Services recommendations (annual 
screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55-77 years, with a smoking history 
of at least 30 pack-years); Ontario, most cost-effective policy from a study for Cancer Care Ontario (annual screening of current 
smokers and former smokers who quit fewer than 10 years ago, aged 55-75 years, with a smoking history of at least 40 pack-
years); USPSTF, US Preventive Services Task Force recommendations (annual screening of current smokers and former smokers 
who quit fewer than 15 years ago, aged 55-80 years, with a smoking history of at least 30 pack-years).
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included younger cohorts than the NLST. A previous 
MISCAN-Lung simulation of the 1950 cohort found 
that 48% of lung cancer cases were diagnosed at stage I 
or II when the USPSTF recommendations were imple-
mented.5 In our current analysis, this proportion was 
only 36.9%. This may be explained by declining smok-
ing trends for younger birth cohorts,8 which cause 
fewer individuals to be  eligible for screening.7 These 
findings underline the necessity of modeling multiple 
birth cohorts when one is assessing lung cancer inter-
ventions over a time period.
Treatment Capacity Requirements
We found that the implementation of lung cancer 
screening would lead to a substantial increase in the 
demand for lung cancer surgery. A previous study that 
investigated the radiological capacity requirements 
for implementing lung cancer screening in the United 
States defined capacity constraints as “a greater than 
5% and (alternatively) greater than 25% projected 
increase in scans.”18 If we apply the 5% increase cri-
terion to our base-case estimates, surgical capacity 
would be restrained in every year, for each scenario, 
and at each adherence level. If we apply the 25% in-
crease criterion to our base-case estimates, capacity 
would be restrained for each scenario and adherence 
level in 2018. By 2023, capacity would be restrained 
for the USPSTF and CMS scenarios with ≥35% adher-
ence and for the Ontario scenarios with ≥50% adher-
ence. Finally, by 2040, capacity would be restrained 
only for the USPSTF scenarios with ≥65% adherence 
and for the CMS scenario with 80% adherence. With 
the treatment proportions from the NLST for screen-
detected cases, surgical capacity constraints would be 
even more pronounced. However, because the NLST 
was conducted under selective and controlled circum-
stances, these estimates should be considered an upper 
bound. Finally, if we applied the 5% criterion to the 
results of the sensitivity analysis with a gradual buildup 
of adherence, surgical capacity would still be restrained 
in each year for each scenario. If we applied the 25% 
increase criterion to the same analysis, capacity would 
be not be restrained in 2018. However, capacity would 
still be restrained in 2023 and 2028 for each scenario.
Thoracic surgeons have lower operative and postop-
erative mortality rates for lung cancer surgery than general 
surgeons.19,20 Consequently, guidelines state that thoracic 
surgeons should be involved in treating screen-detected 
lung cancer.21,22 However, earlier research projected that 
the future demand for thoracic surgeons would increase 
while the supply would decline.23 Without taking into 
account lung cancer screening, Moffatt-Bruce et al24 
reported that by 2035 the caseload per thoracic surgeon 
may increase by 121%. In addition, Edwards et al25 
reported that implementing LDCT lung cancer  screening 
in Canada in 2014 could increase the number of operable 
(ie, stage I and II) lung cancer cases per thoracic surgeon 
by 19.8% in 2030. However, our analysis of NCDB data 
indicates that many stage I and II NSCLC cases in fact 
do not receive surgery. Nevertheless, these studies pro-
vide indications that the current workforce of thoracic 
surgeons may not be able to cope with the additional 
demand caused by lung cancer screening.
Residency training of additional thoracic surgeons 
takes on average 8.7 years.26 However, the projected sur-
gical demand peaked in the first 5 years after the imple-
mentation of screening. This peak would be more spread 
out over time with a gradual buildup of adherence. 
However, delaying the full-scale implementation of lung 
cancer screening may reduce the potential health benefits 
because smoking trends have been declining.7 Therefore, 
our data suggest that training of additional thoracic sur-
geons should start as soon as possible. In the meantime, 
a careful assessment and allocation of available capacity 
should be undertaken to ensure the maximum benefits of 
lung cancer screening.
We found that the overall reduction in the demand 
for radiotherapy (–2.2%) and chemotherapy (–5.4%) was 
smaller than the overall increase in the demand for sur-
gery (+37.0%). This is due to 3 factors. First, patients 
could receive multiple treatments. Second, radiother-
apy and chemotherapy demand first increased because 
of the large incidence peak and then decreased. Third, 
the demand for surgery in the absence of screening was 
much lower than the demand for radiotherapy and che-
motherapy. The initial peak in the demand for radiother-
apy would exceed a 25% increase in comparison with 
no screening only by 2018 and only for the base-case 
USPSTF scenarios with ≥65% adherence and for the 
CMS scenario with 80% adherence. Similarly, the initial 
increase in the demand for chemotherapy in comparison 
with no screening would surpass the 25% mark only in 
2018 for the base-case USPSTF and CMS scenarios with 
80% adherence. Therefore, it is unlikely that the imple-
mentation of lung cancer screening will cause a major 
shortage of radiation oncology or chemotherapy services.
Limitations
There are several potential limitations to the current 
study. First, earlier research has identified treatment 
Lung Cancer Screening Treatment Capacity/Blom et al
2047Cancer  June 15, 2019
disparities among US patients with lung cancer by race27 
and insurance status.28 Although we implicitly accounted 
for these disparities by using the NCDB data, which 
cover 70% of incident cancer cases in the United States, 
MISCAN-Lung currently does not explicitly model the 
effects of these variables.
Second, our model is currently unable to estimate 
lung cancer incidence on a state level, whereas lung can-
cer incidence rates have been shown to vary by state.29 
This should be the subject of future research so that pol-
icy makers can plan treatment capacity on a local level. 
Policy makers should also note that simply increasing the 
number of trained thoracic surgeons may not be suffi-
cient if patients at the highest risk for lung cancer are 
also encumbered by geographical (distance) or financial 
barriers (health insurance) to access.
Third, we have not modeled recurrent tumors. Also, 
the NCDB records only the first course of therapy, which 
is defined as all methods of treatment recorded in the 
treatment plan and administered to the patient before 
disease progression or recurrence. This might lead to an 
underestimation of the total number of treatments 
 required for the implementation of lung cancer screening.
Finally, because we projected demand in the future, 
there may be some future developments that could alter 
our estimates. For instance, we could not project the de-
mand for targeted or immunotherapy agents because these 
are very recent developments. Furthermore, although cur-
rent guidelines recommend stereotactic body radiother-
apy only for patients with medically inoperable early-stage 
NSCLC,6 there is an ongoing debate on its appropriate-
ness in operable patients.30,31 Therefore, the proportion of 
early-stage cases that require radiotherapy could increase 
in the future. Two other developments that may possibly 
alter our estimates are the introduction of risk models 
to select individuals for screening and the use of nodule 
management strategies such as Lung-RADS. Finally, if 
future developments allow clinicians to distinguish indo-
lent screen-detected cancers that would never cause symp-
toms from more aggressive cancers, overdiagnosis could 
decrease. In turn, this could decrease treatment demand.
In conclusion, we show that full-scale implementa-
tion of lung cancer screening in the United States will 
cause a major increase in the demand for lung cancer sur-
gery, with a peak within the first 5 years. The current 
workforce of thoracic surgeons may not be able to cope 
with this increased demand. The question is whether this 
could jeopardize the benefits of screening. Although a 
gradual buildup of adherence could spread the peak in 
surgical demand over time, a delayed implementation 
of screening may reduce the potential health benefits. 
Therefore, implementation of lung cancer screening can 
be done only with a careful assessment and allocation of 
surgical capacity.
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